Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide diphtheria toxoid conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal polysaccharide diphtheria toxoid conjugate vaccine is a vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups. The vaccine works by stimulating the immune system to produce antibodies against meningococcal bacteria. Different formulations protect against different serogroups, with traditional quadrivalent vaccines covering serogroups A, C, Y, and W-135, while the newer pentavalent vaccine (Penmenvy) covers serogroups A, B, C, W, and Y. The vaccines use diphtheria toxoid as a carrier protein to enhance immune response, particularly in younger individuals.
- Brand names
- MenactraMenveoPenmenvy
- Other names
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate VaccineMeningococcal Groups A, B, C, W, and Y Vaccine
02
Targets
Neuraminidase
Beyond the preview
Go deeper on meningococcal polysaccharide diphtheria toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide diphtheria toxoid conjugate vaccine.